Danaher Corporation $DHR Shares Sold by Intrust Bank NA

Intrust Bank NA lessened its holdings in Danaher Corporation (NYSE:DHR) by 10.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,736 shares of the conglomerate’s stock after selling 334 shares during the quarter. Intrust Bank NA’s holdings in Danaher were worth $540,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Boyd Watterson Asset Management LLC OH lifted its position in shares of Danaher by 2.1% in the 2nd quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock worth $499,000 after buying an additional 51 shares during the last quarter. Worth Financial Advisory Group LLC grew its position in shares of Danaher by 4.6% during the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock valued at $236,000 after buying an additional 53 shares during the last quarter. 1834 Investment Advisors Co. raised its stake in Danaher by 3.3% during the first quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate’s stock worth $342,000 after acquiring an additional 54 shares during the period. Bruce G. Allen Investments LLC lifted its holdings in Danaher by 13.1% in the second quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock worth $92,000 after acquiring an additional 54 shares during the last quarter. Finally, Texas Bank & Trust Co lifted its holdings in Danaher by 1.6% in the second quarter. Texas Bank & Trust Co now owns 3,567 shares of the conglomerate’s stock worth $705,000 after acquiring an additional 55 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the sale, the senior vice president directly owned 2,625 shares in the company, valued at approximately $552,352.50. The trade was a 66.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Teri List sold 2,778 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 29,728 shares of company stock valued at $6,448,990. Company insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on DHR. Royal Bank Of Canada set a $241.00 target price on Danaher in a report on Tuesday, September 2nd. Evercore ISI boosted their price objective on Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Barclays upped their price objective on Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. TD Cowen raised their target price on Danaher from $250.00 to $260.00 and gave the company a “buy” rating in a research note on Wednesday, October 22nd. Finally, Rothschild & Co Redburn reissued a “neutral” rating and set a $220.00 price target (down previously from $245.00) on shares of Danaher in a report on Wednesday, October 8th. Eighteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $243.39.

Danaher Stock Down 0.4%

Shares of Danaher stock opened at $220.41 on Tuesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $258.23. The business’s fifty day moving average price is $206.07 and its two-hundred day moving average price is $201.28. The company has a market capitalization of $155.69 billion, a P/E ratio of 45.45, a PEG ratio of 3.28 and a beta of 0.81.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.17. The company had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.71 earnings per share. As a group, research analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were paid a dividend of $0.32 per share. The ex-dividend date of this dividend was Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s dividend payout ratio (DPR) is presently 26.39%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.